GW Pharma Reveals Pricing on First FDA Approved Cannabis Derived Prescription Antiepileptic Drug

GW Pharmaceuticals (NASDAQ: GWPH) announced the price of Epidiolex® on August 7th during its fiscal 2018 Q3 conference call with investors and analysts.

Epidiolex® is the company’s antiepileptic drug that received FDA approval on its effectiveness to treat seizures associated with Lennox-Gastaut syndrome (LGS) and Dravet syndrome. Earlier in 2018, Epidiolex® became the first FDA approved pharmaceutical drug to contain non-psychoactive cannabidiol (CBD) that was derived from the cannabis plant.

During the company’s conference call it was revealed that the cost of Epidiolex® would be an estimated $32,000 per year but varies depending on the patient’s weight and the dosage amount. The pricing of Epidiolex® was made to be along the lines of other anti-seizure medications that are often prescribed to those with LGS and Dravet syndrome.

The company reported that Epidiolex® is on schedule to be launched in the fall of 2018.

GW Pharma Reveals Pricing on First FDA Approved Cannabis Derived Prescription Antiepileptic Drug

About Cannin.com: Your Marijuana Stocks Resource

Cannin is your #1 resource for marijuana stocks. Our global team of experts evaluates all emerging marijuana stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best marijuana stock investments for 2020.

Use Cannin as your resource for:

Is it too late to invest in marijuana stocks? No! This is the perfect time to invest.

Many market analysts expect the legal marijuana industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in marijuana stocks is now.

Are you interested in marijuana stocks like Curaleaf, Trulieve, Aurora Cannabis, or Charlotte’s Web,?

Are you looking to buy stock in marijuana companies for 2020? Interested in emerging penny marijuana stocks? Looking for the best Canadian marijuana stocks to invest in? We can help.

Predict price movements of marijuana stocks several hours in advance with our proprietary algorithmic stock trading software.

+25% Gains in 2020
+49.8% Gains in 2019
108% Backtested since 2012

We’re so confident you’ll love our algotrading marijuana stock signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best marijuana stocks – we’ll show you how at cannin.com.

Marijuana Stocks, Pot Stocks, Algorithmic Stock Trading, Best Hemp Stocks 2020

GW Pharma Reveals Pricing on First FDA Approved Cannabis Derived Prescription Antiepileptic Drug